Literature DB >> 12462421

Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray.

Silvia Mandel1, Edna Grünblatt, Gila Maor, Moussa B H Youdim.   

Abstract

Recently, we reported specific brain gene expression changes in the chronic MPTP model inthe late stage of degeneration, employing cDNA expression array, which indicate a "domino" cascade of events involved in neuronal cell death. In an attempt to elucidate early gene expression profile in the region of the substantia nigra (SN) and the striatum of acute MPTP-treated mice (3-24 h), we elected a restricted number of genes affected by the long-term MPTP treatment, and their expression was examined. Specifically, we detected alterations in the expression of genes implicated in oxidative-stress, inflammatory processes, signal transduction and glutamate toxicity. These pro-toxic genes appear to be compensated by the elevated expression in trophic factors and antioxidant defenses, which are also activated by short exposure to MPTP. The time course of these gene expression changes indicates the importance of investigating the early gene cascade of events occurring prior to late nigrostriatal dopamine neuronal cell death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12462421     DOI: 10.1023/a:1020989812576

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  64 in total

Review 1.  Glial cells and Parkinson's disease.

Authors:  E C Hirsch
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

2.  Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.

Authors:  E Grünblatt; S Mandel; G Maor; M B Youdim
Journal:  J Neurochem       Date:  2001-07       Impact factor: 5.372

3.  Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum.

Authors:  M Mogi; A Togari; M Ogawa; K Ikeguchi; N Shizuma; D Fan; I Nakano; T Nagatsu
Journal:  Neurosci Lett       Date:  1998-06-26       Impact factor: 3.046

Review 4.  Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease.

Authors:  A K Raina; X Zhu; C A Rottkamp; M Monteiro; A Takeda; M A Smith
Journal:  J Neurosci Res       Date:  2000-07-15       Impact factor: 4.164

5.  Neuroprotective effects of interleukin-10 following excitotoxic spinal cord injury.

Authors:  K L Brewer; J R Bethea; R P Yezierski
Journal:  Exp Neurol       Date:  1999-10       Impact factor: 5.330

Review 6.  Role of redox-regulated transcription factors in inflammation, aging and age-related diseases.

Authors:  Y Lavrovsky; B Chatterjee; R A Clark; A K Roy
Journal:  Exp Gerontol       Date:  2000-08       Impact factor: 4.032

Review 7.  Pharmacogenomics of neurodegenerative diseases.

Authors:  D Maimone; R Dominici; L M Grimaldi
Journal:  Eur J Pharmacol       Date:  2001-02-09       Impact factor: 4.432

8.  The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

Authors:  D Ben-Shachar; G Eshel; J P Finberg; M B Youdim
Journal:  J Neurochem       Date:  1991-04       Impact factor: 5.372

9.  Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients.

Authors:  H Shimura; N Hattori; S Kubo; M Yoshikawa; T Kitada; H Matsumine; S Asakawa; S Minoshima; Y Yamamura; N Shimizu; Y Mizuno
Journal:  Ann Neurol       Date:  1999-05       Impact factor: 10.422

10.  The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+).

Authors:  S Carboni; F Melis; L Pani; M Hadjiconstantinou; Z L Rossetti
Journal:  Neurosci Lett       Date:  1990-09-04       Impact factor: 3.046

View more
  22 in total

1.  Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.

Authors:  Moussa B.H. Youdim; Edna Grünblatt; Yona Levites; Gila Maor; Silvia Mandel
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 2.  Expression profile analysis of neurodegenerative disease: advances in specificity and resolution.

Authors:  Jason G Glanzer; Phillip G Haydon; James H Eberwine
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

3.  Mining microarrays for metabolic meaning: nutritional regulation of hypothalamic gene expression.

Authors:  Charles V Mobbs; Kelvin Yen; Jason Mastaitis; Ha Nguyen; Elizabeth Watson; Elisa Wurmbach; Stuart C Sealfon; Andrew Brooks; Stephen R J Salton
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 4.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

Review 5.  Strategies to unravel molecular codes essential for the development of meso-diencephalic dopaminergic neurons.

Authors:  F M J Jacobs; S M Smits; K J M Hornman; J P H Burbach; M P Smidt
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

6.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

Review 7.  Current status and future directions of gene expression profiling in Parkinson's disease.

Authors:  James G Greene
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

8.  Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.

Authors:  Silvia Mandel; Gila Maor; Moussa B H Youdim
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.

Authors:  Nadia G Innamorato; Agnieszka Jazwa; Ana I Rojo; Concepción García; Javier Fernández-Ruiz; Anna Grochot-Przeczek; Anna Stachurska; Alicja Jozkowicz; Jozef Dulak; Antonio Cuadrado
Journal:  PLoS One       Date:  2010-07-28       Impact factor: 3.240

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.